Core Viewpoint - The article highlights the strong performance of Fuhong Hanlin (2696.HK) amidst a general decline in the Hong Kong stock market, driven by the approval of its biosimilar products by the FDA, indicating significant growth potential for the company [1] Group 1: Company Performance - Fuhong Hanlin's stock rose by 4.94% to HKD 80.8, approaching its historical high of HKD 85.95 reached on August 21 [1] - The company's stock has increased over 2.4 times year-to-date, significantly outperforming the Hang Seng Index, which has risen by over 26% in the same period [1] Group 2: Regulatory Approval - The FDA approved the market applications for two biosimilar products: BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), which are biosimilars to PROLIA® and XGEVA® respectively [1] - This approval marks another milestone for Fuhong Hanlin in gaining regulatory recognition for its self-developed and self-manufactured biosimilars in the U.S. market [1] Group 3: Shareholder Confidence - Point72 Associates, LLC increased its stake in Fuhong Hanlin by approximately HKD 20.37 million, acquiring 243,800 shares, raising its total holdings to 8.24 million shares [1] - Following this purchase, the ownership percentage increased from 4.89% to 5.04%, reflecting strong confidence from shareholders in the company's long-term growth and investment value [1]
港股异动丨旗下地舒单抗成功出海、股东大额增持！复宏汉霖收涨4.94% 年内累涨超2.4倍